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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S324and, in addition to its powerful antioxidant activity, it may exert mod-
ulatory effects on different signalling pathways.
Methods: The immortalized human cell line C-28/I2 and primary cul-
tures of human chondrocytes (prepared from fragments of articular
cartilage obtained from adult OA patients undergoing knee arthro-
plasty) were treated with HT, 30 minutes before exposition to hydrogen
peroxide to induce oxidative stress and samples were collected at dif-
ferent times. We tested cell viability through reading on MUSE Cell
Analyzer. The expression of genes and proteins known or potentially
implicated in OA was evaluated by Real-Time RT-PCR assay and by
Western blot method, respectively. By 6 different algorithms (TargetS-
can, miRanda, PICTAR4, miRDB, miRWalk, RNA22) bioinformatic anal-
ysis selected possible candidate microRNAs that could interact with
targets of interest. Subsequently we veriﬁed by Real Time RT-PCR assay
possible variations in the expression of these microRNAs after
treatments.
Results:We evaluated the gene expression of runt-related transcription
factor-2 and matrix metalloproteinase-13, two molecular markers of
OA, in human primary chondrocytes cultured in monolayer. HT pre-
vents the increase induced by oxidative stress in the mRNA amount of
bothmarkers. Moreover this compound is able to reduce signiﬁcantly C-
28/I2 cells death. In order to investigate a possible involvement of
autophagic process in this context, we evaluated the protein expression
of LC3 II (active form associated to autophagosomes), after oxidative
stress in presence or in absence of HT. We found that HT induces an
increase of protein levels of this autophagic marker, suggesting a pos-
sible mechanism of cytoprotection. This effect of HT on autophagy may
be promoted by modulating several effectors such as AMP-activated
protein kinase (AMPK) and the NAD-dependent deacetylase Sirtuin-1
(SIRT-1). Indeed HT causes the increase of phospho-AMPK and SIRT-1
protein levels. At the same time, this compound is able to decrease the
amount of microRNA-9, which can target SIRT-1mRNA thusmodulating
its expression.
Conclusions: This study suggests newmolecular mechanisms by which
HT may prevent some aspects of OA pathogenesis and progression.
Indeed the beneﬁcial action of HT in this context seems to be related to
the stimulation of autophagy. These data indicate that HT can be con-
sidered an attractive tool for the prevention of OA.This work was sup-
ported by FIRB (Ministero dell’istruzione, dell’Universita e della Ricerca,
Italy) grant RBAP10KCNS.
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Purpose: To assess the clinical efﬁcacy and safety of oral ginger for
symptomatic treatment of osteoarthritis (OA).
Methods: A systematic literature search was undertaken in the biblio-
graphic databases: MEDLINE via PubMed from 1950, EMBASE via OVID
from 1980, CINAHL via EBSCO from 1981,Web of Science from 1900, and
Sciﬁnder from 1907, as well as The Cochrane Central Register of Con-
trolled Trials, all up to August 2013. Inclusion criteriawere: Randomized
trials comparing any oral ginger preparation (consisting only of extracts
of ginger species) with placebo, where the participants were aged 18 or
over with OA in any joint. Major outcomes were reduction in pain and
improvement in physical function. Harm was assessed as withdrawals
due to adverse events. The efﬁcacy effect size was estimated using
Hedges’ standardized mean difference (SMD) and safety using the risk
ratio (RR). Standard random-effects meta-analysis was used by default
(conﬁrmed by a ﬁxed-effects model), and inconsistency was evaluated
by the I-squared index (I2).
Results: Out of 113 retrieved references, 108 were discarded, leaving
ﬁve placebo-controlled trials (757 patients, mainly with knee and/or
hip OA) for the meta-analysis. The majority reported relevantrandomization procedures and blinding but applied an inadequate
intention-to-treat (ITT) approach. Pain reduction following ginger
intake revealed a low degree of heterogeneity among trials (I2 ¼ 27%),
with a statistically signiﬁcant SMD of -0.30 (95% CI: [-0.50, -0.09], P ¼
0.005) in favour of ginger. Ginger showed a statistically signiﬁcantly
larger improvement in physical function than placebo SMD¼ -0.22 (95%
CI: [-0.39, -0.04]; P¼ 0.01; I2¼ 0%). Based on data from three trials (328
patients), patients given ginger were more than twice as likely to dis-
continue treatment due to adverse events compared to placebo (RR ¼
2.33; 95% CI: [1.04, 5.22]; P ¼ 0.04; I2 ¼ 0%).
Conclusions: Ginger was found modestly efﬁcacious in reducing pain
and improve physical function in clinical trials of patients with mainly
knee and/or hip OA. Ginger was also reasonably safe since reported
adverse events were mild and reversible. We judged the evidence to be
of moderate quality, based on the small number of participants and
non-adequate ITT analysis (with the latter risk of bias item leading to
downgrading from high to moderate conﬁdence in the estimates).
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Purpose: Osteoarthritis (OA) is a signiﬁcant worldwide health problem
owing to the progressive and debilitating nature of the condition, which
results in highmorbidity and amarked decrease in the quality of life. OA
involves the progressive degeneration of articular cartilage with a
remodeling of subchondral bone and synovitis.
The objective is to evaluate the potential anti-arthritic activity of Acti-
Joint, a formulation that includes CS Bioactive (Chondroitin Sulfate
100% purity ,CS), Glucosamine (GLU) and Hyal-Joint, a natural ingre-
dient rich in sodium hyaluronate in an in vitro chondrocyte model and
in the collagen-induced arthritis (CIA) model in rats.
Methods: An in vitro study was performed using human osteoarthritic
chondrocytes cultured in alginate (n¼ 3) in order to evaluate the
potential chondroprotective activity of Acti-Joint. Effects on degra-
dation of the extracellular matrix were determined by measuring
metalloproteinase-1 (MMP-1) and metalloproteinase-13 (MMP-13)
activities by ELISA (R&D kits). The synthesis of sulfated glyco-
saminoglycans (GAGs) was measured in chondrocytes by determining
the incorporation of [35S]sulfate into cetylpyridiniumchloride-precip-
itable (CPC) GAGs by liquid scintillation analysis.
The anti-arthritic activity was investigated in the CIA model in rats.
Female rats with developing type II collagen arthritis (n ¼ 11) were
treated orally once daily with distilled water (Vehicle group) or Acti-
Joint (160 mg/kg) starting 10 days prior to disease induction through
the end of the study (day 35). Dexamethasone, the positive control
group, was administered once daily starting at day 0. The arthritic
clinical score for each animal was examined starting at day 7. A clinical
score was given to each individual paw and was based on 0-4 scale. The
sum of all paws was calculated for each animal. In addition, a cytokine
analysis on the left hind joint was performed: IL-6 and TNFa gene
expression.
Results: The in vitro assays showed that Acti-Joint leads to a stat-
istically signiﬁcant reduction of MMP-1 andMMP-13 activities (p<0.05)
and also a stimulation of the synthesis of GAGs compared to the Control.
Acti-Joint showed better efﬁcacy than the standard combination GLU
þ CS, being CS of a lower quality and uncertain traceability. In the
experimental conditions of the in vivo study, we found that this for-
mulation reduced about 10% the clinical score after 3 weeks of the
arthritis induction. This was accompanied by a signiﬁcant reduction of
the pro-inﬂammatory cytokines IL-6 (74%) and TNFa (70%) levels
compared to Vehicle group.
Conclusions: The present study indicates that Acti-Joint has chon-
droprotective and anti-inﬂammatory activities. Thus, this natural
